The esoteric testing market is experiencing significant growth, driven by advancements in diagnostic technologies, increasing prevalence of chronic diseases, and a growing emphasis on personalized medicine. This article provides a comprehensive overview of the market, highlighting key players, technological trends, market drivers and restraints, segmentation, regional insights, and future prospects.

In 2024, the global esoteric testing market size was valued at USD 26.81 billion. It is expected to increase to USD 29.56 billion in 2025 and reach USD 60.93 billion by 2032, growing at a compound annual growth rate (CAGR) of 10.9% over the forecast period.

Top Companies in the Market

• Eurofins Scientific (Luxembourg)
• Quest Diagnostics Incorporated (U.S.)
• Laboratory Corporation of America Holdings (U.S.)
• ACM Global Laboratories (U.S.)
• Mayo Foundation for Medical Education and Research (U.S.)
• Sonic Healthcare Limited (Australia)
• ARUP Laboratories (U.S.)
• OPKO Health, Inc. (U.S.)
• Thyrocare (India)

Key Industry Development

In August 2022, Myriad Genetics, Inc. announced that Japan’s Ministry of Health granted expanded coverage for its BRAC Analysis Diagnostic System. This system is used as a companion diagnostic to identify patients with breast cancer, enhancing the scope of esoteric testing in oncology.

Market Drivers & Restraints

Drivers

• Rising Prevalence of Chronic Diseases: The increasing incidence of chronic conditions such as cancer, diabetes, and autoimmune disorders necessitates specialized diagnostic tests, propelling market growth.
• Technological Advancements: Innovations in molecular diagnostics, next-generation sequencing, and mass spectrometry have improved the accuracy and efficiency of esoteric tests.